Status:
NOT_YET_RECRUITING
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions:
Advanced Solid Tumor
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a multicenter, open-label phase I/II study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.
Eligibility Criteria
Inclusion
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-75 years of age.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
- PART 1: Histologically confirmed unresectable locally advanced, recurrent, or metastatic solid tumors.PART 2 Cohort A: Histologically confirmed unresectable locally advanced, recurrent, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. Cohort B: Histologically confirmed unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. Cohort C: Histologically confirmed unresectable locally advanced, recurrent, or metastatic other solid tumors.
- Life expectancy ≥ 3 months.
Exclusion
- participants were deemed unsuitable for participating in the study by the investigator for any reasons.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT07142837
Start Date
September 1 2025
End Date
December 1 2027
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hosptial
Beijing, Beijing Municipality, China